Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.

In any case, there is an overall trend towards better outcomes in cohort B.

also in 4,871 other papers

In our study, although the difference in the primary and secondary endpoints were not statistically significant, there was a clear trend towards better outcomes in patients receiving metformin despite having almost similar characteristics (such as type of ICIs received, prior use of immunotherapies/ chemotherapies, mutation load, type of mutations, the TNM staging and the metastatic sites involved).

also in 19,460 other papers

Though older, patients in cohort B showed a trend toward better outcomes.

also in 53,322 other papers